Organogenesis Holdings Inc.

Organogenesis Holdings Inc. develops, manufactures, and sells regenerative medicine products for advanced wound care and for surgical and sports medicine uses. Its portfolio includes tissue-based and cell-based products used by hospitals, wound care centers, ambulatory surgery centers, physician offices, and government facilities, with most sales generated in the United States and additional commercial activity in select international markets.

10,6 %

6,6 %

+17,0 %

3.62

3.32

— Organogenesis Holdings Inc.
%
Advanced Wound Care70% Biologic and tissue-based products used to support healing of chronic and complex wounds.
Surgical & Sports Medicine25% Products used in surgical procedures and orthopedic or sports medicine applications.
International Distribution5% Commercial sales of selected products in markets outside the United States.

Organogenesis sells primarily to healthcare providers that treat chronic wounds or perform procedures requiring...

  • Hospitalsprimary

    Buy advanced wound care and surgical products for procedure-based healing and inpatient/outpatient use.

  • Wound care centersprimary

    Purchase skin substitutes and biologics for chronic wound treatment protocols.

  • Ambulatory surgery centerssecondary

    Use surgical and sports medicine tissue products in outpatient procedures.

  • Physician officessecondary

    Buy products for office-based wound management and follow-up care.

  • Government facilitiessecondary

    Purchase through public healthcare channels where reimbursement and coverage rules matter.

The company is primarily a U.S. business, and its direct sales force in the United States represents the core of...

  • •United States is the main commercial market and sales base
  • •Direct sales force covers U.S. wound care customers
  • •Switzerland is an active international market for Apligraf and NuShield
  • •Saudi Arabia and Kuwait are served through independent sales agents
  • •Mexico has marketing registration for Dermagraft, though not distributed

Organogenesis focuses on expanding clinical evidence for its products, because outcomes data supports physician...

01
Generate clinical and real-world outcomes datamedium-term

Evidence supports physician confidence, payer coverage, and product differentiation.

02
Strengthen U.S. commercial executionshort-term

The company relies on direct sales relationships and field coverage to drive utilization.

03
Expand manufacturing and operating infrastructuremedium-term

Production capacity and facility readiness support growth and product availability.

04
Broaden geographic reach selectivelylong-term

International registrations can extend the product portfolio beyond the U.S. market.

The business is exposed to reimbursement decisions, especially Medicare coverage and payment policy for skin substitute...

high

Medicare coverage and reimbursement changes

Demand for wound care products depends heavily on payer payment policy and coverage decisions.

Scope
Advanced wound care and skin substitute products
Materiality
high
high

Proposed non-coverage LCDs for certain products

If finalized, non-coverage could reduce utilization of specific products in Medicare populations.

Scope
Skin substitute grafts/CTPs for DFUs and VLUs
Materiality
high
high

Regulatory and quality compliance

FDA and other healthcare regulations govern product approvals, manufacturing, and distribution.

Scope
PMA, 510(k), HCT/P-regulated products
Materiality
high
medium

Intense competition and product substitution

The company competes against skin substitutes, placental-based products, and traditional wound care.

Scope
Advanced wound care and surgical markets
Materiality
high
medium

IT and information security disruptions

Operational systems support sales, manufacturing, and customer service, so outages can impair execution.

Scope
Commercial and manufacturing infrastructure
Materiality
medium
Revenue recognition timing
Affects quarterly revenue comparability and reported growth rates
Reserves for returns, discounts, and GPO rebates
Affects net revenue and margin presentation
Seasonality
Creates uneven quarterly revenue and working capital patterns
Impairment and estimate judgments
Can materially affect earnings and balance sheet values

ORAGENICS INC

OGEN · Pharmaceutical Preparations

Orchestra BioMed Holdings, Inc.

OBIO · Surgical & Medical Instruments & Apparatus

SCYNEXIS INC

SCYX · Pharmaceutical Preparations

Organon & Co.

OGN · Pharmaceutical Preparations

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CELZ · Biological Products, (No Diagnostic Substances)

SOLIGENIX, INC.

SNGX · Pharmaceutical Preparations

: 29.4.2026